Metalloproteinases and their inhibitors in neurological disease

Area of Science:

• Biochemistry
• Pharmacology
• Neurology

Background:

• Matrix metalloproteinases (MMPs) are enzymes degrading the extracellular matrix.
• MMPs are implicated in physiological and pathological processes, including neuroinflammation in cerebrovascular diseases.
• Synthetic MMP inhibitors have shown limited clinical success, with some discontinued due to adverse effects.

Purpose of the Study:

• To review matrix metalloproteinase (MMP) inhibition from a clinical perspective.
• To explore the potential therapeutic applications of MMP inhibitors in future treatments.
• To assess the role of MMPs in neurodegenerative and cerebrovascular diseases.

Main Methods:

• Literature review of clinical trials and studies on MMP inhibitors.
• Analysis of the efficacy and safety of synthetic MMP inhibitors in oncological and other trials.
• Evaluation of tetracyclines as MMP inhibitors in submicrobial doses for neurological conditions.

Main Results:

• Synthetic MMP inhibitors have largely failed in clinical trials, particularly in oncology, with significant adverse reactions reported.
• Tetracyclines, at submicrobial doses, exhibit MMP inhibitory properties.
• The efficacy of tetracyclines in neurological conditions and cerebrovascular diseases remains unproven in placebo-controlled trials.

Conclusions:

• Current synthetic MMP inhibitors lack clinical efficacy and present safety concerns.
• Submicrobial tetracyclines represent a potential therapeutic strategy for MMP-related conditions, but further research is needed.
• The role of MMP inhibition in neuroprotection and cerebrovascular disease treatment requires further investigation.